Integrative pan-cancer analysis reveals AARS2 as a lactylation-associated biomarker and therapeutic target in colon adenocarcinoma - PubMed
5 hours ago
- #colon adenocarcinoma
- #lactylation
- #AARS2
- AARS2 identified as a lactylation-associated biomarker and therapeutic target in colon adenocarcinoma (COAD).
- Lactylation, driven by lactate, links tumor metabolism to immunosuppression, promoting malignancy and immune evasion.
- Multi-omics analysis (bulk RNA-seq, single-cell RNA-seq, spatial transcriptomics) used to study lactylation-related genes (LRGs).
- AARS2 upregulation in COAD correlates with poor prognosis and immunosuppressive tumor microenvironment.
- AARS2 knockdown reduces lactate accumulation and protein lactylation, affecting immune-related gene expression.
- Potential role of AARS2 in regulating the cGAS-STING pathway via lactylation dynamics.